Tags

Type your tag names separated by a space and hit enter

Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study.
Am J Ophthalmol. 2010 Apr; 149(4):585-93.AJ

Abstract

PURPOSE

To report the long-term results of 44 keratoconic eyes treated by combined riboflavin ultraviolet A collagen cross-linking in the first Italian open, nonrandomized phase II clinical trial, the Siena Eye Cross Study.

DESIGN

Perspective, nonrandomized, open trial.

METHODS

After Siena University Institutional Review Board approval, from September 2004 through September 2008, 363 eyes with progressive keratoconus were treated with riboflavin ultraviolet A collagen cross-linking. Forty-four eyes with a minimum follow-up of 48 months (mean, 52.4 months; range, 48 to 60 months) were evaluated before and after surgery. Examinations comprised uncorrected visual acuity, best spectacle-corrected visual acuity, spherical spectacle-corrected visual acuity, endothelial cells count (I Konan, Non Con Robo; Konan Medical, Inc., Hyogo, Japan), optical (Visante OCT; Zeiss, Jena, Germany) and ultrasound (DGH; Pachette, Exton, Pennsylvania, USA) pachymetry, corneal topography and surface aberrometry (CSO EyeTop, Florence, Italy), tomography (Orbscan IIz; Bausch & Lomb Inc., Rochester, New York, USA), posterior segment optical coherence tomography (Stratus OCT; Zeiss, Jena, Germany), and in vivo confocal microscopy (HRT II; Heidelberg Engineering, Rostock, Germany).

RESULTS

Keratoconus stability was detected in 44 eyes after 48 months of minimum follow-up; fellow eyes showed a mean progression of 1.5 diopters in more than 65% after 24 months, then were treated. The mean K value was reduced by a mean of 2 diopters, and coma aberration reduction with corneal symmetry improvement was observed in more than 85%. The mean best spectacle-corrected visual acuity improved by 1.9 Snellen lines, and the uncorrected visual acuity improved by 2.7 Snellen lines.

CONCLUSIONS

The results of the Siena Eye Cross Study showed a long-term stability of keratoconus after cross-linking without relevant side effects. The uncorrected visual acuity and best spectacle-corrected visual acuity improvements were supported by clinical, topographic, and wavefront modifications induced by the treatment.

Authors+Show Affiliations

Department of Ophthalmology and Neurosurgery, Santa Maria delle Scotte Hospital, Siena University, Siena, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article

Language

eng

PubMed ID

20138607

Citation

Caporossi, Aldo, et al. "Long-term Results of Riboflavin Ultraviolet a Corneal Collagen Cross-linking for Keratoconus in Italy: the Siena Eye Cross Study." American Journal of Ophthalmology, vol. 149, no. 4, 2010, pp. 585-93.
Caporossi A, Mazzotta C, Baiocchi S, et al. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. Am J Ophthalmol. 2010;149(4):585-93.
Caporossi, A., Mazzotta, C., Baiocchi, S., & Caporossi, T. (2010). Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. American Journal of Ophthalmology, 149(4), 585-93. https://doi.org/10.1016/j.ajo.2009.10.021
Caporossi A, et al. Long-term Results of Riboflavin Ultraviolet a Corneal Collagen Cross-linking for Keratoconus in Italy: the Siena Eye Cross Study. Am J Ophthalmol. 2010;149(4):585-93. PubMed PMID: 20138607.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. AU - Caporossi,Aldo, AU - Mazzotta,Cosimo, AU - Baiocchi,Stefano, AU - Caporossi,Tomaso, Y1 - 2010/02/06/ PY - 2009/06/02/received PY - 2009/10/20/revised PY - 2009/10/31/accepted PY - 2010/2/9/entrez PY - 2010/2/9/pubmed PY - 2010/4/23/medline SP - 585 EP - 93 JF - American journal of ophthalmology JO - Am J Ophthalmol VL - 149 IS - 4 N2 - PURPOSE: To report the long-term results of 44 keratoconic eyes treated by combined riboflavin ultraviolet A collagen cross-linking in the first Italian open, nonrandomized phase II clinical trial, the Siena Eye Cross Study. DESIGN: Perspective, nonrandomized, open trial. METHODS: After Siena University Institutional Review Board approval, from September 2004 through September 2008, 363 eyes with progressive keratoconus were treated with riboflavin ultraviolet A collagen cross-linking. Forty-four eyes with a minimum follow-up of 48 months (mean, 52.4 months; range, 48 to 60 months) were evaluated before and after surgery. Examinations comprised uncorrected visual acuity, best spectacle-corrected visual acuity, spherical spectacle-corrected visual acuity, endothelial cells count (I Konan, Non Con Robo; Konan Medical, Inc., Hyogo, Japan), optical (Visante OCT; Zeiss, Jena, Germany) and ultrasound (DGH; Pachette, Exton, Pennsylvania, USA) pachymetry, corneal topography and surface aberrometry (CSO EyeTop, Florence, Italy), tomography (Orbscan IIz; Bausch & Lomb Inc., Rochester, New York, USA), posterior segment optical coherence tomography (Stratus OCT; Zeiss, Jena, Germany), and in vivo confocal microscopy (HRT II; Heidelberg Engineering, Rostock, Germany). RESULTS: Keratoconus stability was detected in 44 eyes after 48 months of minimum follow-up; fellow eyes showed a mean progression of 1.5 diopters in more than 65% after 24 months, then were treated. The mean K value was reduced by a mean of 2 diopters, and coma aberration reduction with corneal symmetry improvement was observed in more than 85%. The mean best spectacle-corrected visual acuity improved by 1.9 Snellen lines, and the uncorrected visual acuity improved by 2.7 Snellen lines. CONCLUSIONS: The results of the Siena Eye Cross Study showed a long-term stability of keratoconus after cross-linking without relevant side effects. The uncorrected visual acuity and best spectacle-corrected visual acuity improvements were supported by clinical, topographic, and wavefront modifications induced by the treatment. SN - 1879-1891 UR - https://www.unboundmedicine.com/medline/citation/20138607/Long_term_results_of_riboflavin_ultraviolet_a_corneal_collagen_cross_linking_for_keratoconus_in_Italy:_the_Siena_eye_cross_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9394(09)00808-3 DB - PRIME DP - Unbound Medicine ER -